Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
05:07pm, Friday, 22'nd Mar 2024
Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite
Did Eli Lilly Just One-Up Novo Nordisk?
07:15am, Friday, 22'nd Mar 2024
Eli Lilly and Novo Nordisk are fierce competitors in the diabetes and obesity markets. Each company is investing heavily to scale up production to meet demand.
Could Viking Therapeutics Become the Next Eli Lilly?
04:55am, Friday, 22'nd Mar 2024
Eli Lilly's weight loss drugs are helping it conquer what may become a $100 billion market. Viking Therapeutics recently announced promising trial data for its weight loss candidate -- which works in
Medicare allows coverage of Wegovy for heart patients
03:40pm, Thursday, 21'st Mar 2024
Older adults may now get Medicare coverage for the popular obesity drug Wegovy, so long as they're using it to cut their risk of serious heart problems and not for weight loss alone, according to new
Amazon's 1-2 Punch: AI-Powered Listings and Eli Lilly Deal Make AMZN a Must-Buy
06:25am, Thursday, 21'st Mar 2024
By now, it's well established that Amazon (NASDAQ: AMZN ) is not only an e-commerce juggernaut and cloud-computing contender, but is also deeply involved in artificial intelligence technology. As Ama
Eli Lilly and Novo can 'coexist for awhile' in the weight-loss drug space, says BMO's Evan Seigerman
06:27pm, Wednesday, 20'th Mar 2024
Evan Seigerman, BMO Capital, joins 'Fast Money' to discuss BMO's inaugural GLP-1 conference.
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?
08:30am, Wednesday, 20'th Mar 2024
Novo Nordisk's shares have benefited from some recent positive developments. The delay in the approval of donanemab has held back Eli Lilly's valuation.
3 Stocks Ready to Ride the Bull Higher
06:00am, Wednesday, 20'th Mar 2024
Despite a few soft weeks, the stock market rally that began at the end of 2022 remains intact. We're now seeing signs that the rally is broadening out beyond the popular mega-cap technology stocks to
A new study cites the health risks of intermittent fasting. Could it lift Ozempic sales?
07:01pm, Tuesday, 19'th Mar 2024
A new medical study is raising concerns over whether intermittent fasting, a weight-loss method that's gained attention in recent years, could pose heart-health risks.
Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing
06:51pm, Tuesday, 19'th Mar 2024
Eli Lilly (LLY) closed the most recent trading day at $772.78, moving +1.33% from the previous trading session.
Time to be "Overweight" Viking Therapeutics
04:00pm, Tuesday, 19'th Mar 2024
A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 19'th Mar 2024
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Pick Eli Lilly Stock After A 4x Rise In Three Years?
08:00am, Tuesday, 19'th Mar 2024
Eli Lilly stock (NYSE: LLY) has seen phenomenal gains of 345% from levels of $170 in early January 2021 to around $755 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year pe
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
05:50am, Tuesday, 19'th Mar 2024
Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.
Wall Street's Favorite Growth Stocks? 7 Names That Could Make You Filthy Rich
04:10pm, Monday, 18'th Mar 2024
Growth stocks are rising, offering stellar gains so far this year. The tech-heavy S&P 500 continues to post new highs, with investors shrugging off inflation concerns.
